
Gene therapy for limb-girdle muscular dystrophy shows promise
Atamyo Therapeutics has shared the first clinical results for its ATA-200 gene therapy in LGMD-2C/R5 limb-girdle muscular dystrophy associated with γ-sarcoglycan deficiency (SGCG, gamma-sarcoglycanopathy). The results are from a Phase Ib/II clinical trial conducted at the Powell Gene Therapy Center at the University of Florida, supported by… Read More
